XSHE
300452
Market cap468mUSD
Oct 09, Last price
13.55CNY
1D
1.19%
1Q
12.73%
Jan 2017
-21.47%
IPO
189.99%
Name
Anhui Sunhere Pharmaceutical Excipients Co Ltd
Chart & performance
P/E
17.99
P/S
3.37
EPS
0.75
Div yield, %
2.24%
Shrs. gr., 5y
0.59%
Rev. gr., 5y
8.86%
Revenues
943m
+6.82%
Net income
177m
+47.84%
CFO
192m
+62.25%
Dividend
Jun 10, 20260.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Huainan, China, Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. operates within China as a manufacturer and seller of pharmaceutical excipients and specialized medicines. The company's diverse offerings include cellulose, starch, povidone, stearic acid, coating powders, resins, and food additives. Furthermore, it exports these products internationally to regions such as Europe, the United States, and Southeast Asia.
Key people
Changhong Wu
Chairman of the Board · since 2025
Zhenglong Yin
Chairman of the Board, General Manager
Zihu Liu
Deputy General Manager · since 2024
Lisheng Pan
Deputy General Manager · since 2024
Daocai Song
Deputy General Manager, Director · since 2024
Tangdong Zhu
Finance Director, Deputy General Manager · since 2024
Hao Hu
Secretary of the Board
Hanfang Lei
Director · since 2024
Lu Liu
Director · since 2024
Ping Lin
Independent Director · since 2024
Independent Director · since 2024
Independent Director · since 2024
Headquarters & legal address
安徽省淮南市经济技术开发区
淮南市, AH 230000
CN
淮南市, AH 230000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||